Street Calls of the Week
SAN DIEGO - LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company with a market capitalization of $1.28 billion and currently trading near its 52-week high of $46.21, announced Tuesday that its presbyopia treatment VIZZ (aceclidine ophthalmic solution) 1.44% is now available in the United States, with professional samples being distributed nationwide to eye care professionals.
The company stated that commercial product shipments to consumers will begin in October through its ePharmacy partner, with broader availability expected through retail pharmacies by mid-Q4 2025. According to InvestingPro data, LENZ has demonstrated strong momentum with a 89% return over the past year and maintains a healthy financial position with a current ratio of 20.54, indicating robust liquidity to support its commercial launch.
VIZZ, which received FDA approval as the first aceclidine-based eye drop for presbyopia, is designed to improve near vision in adults for up to 10 hours. Presbyopia, a condition affecting approximately 128 million adults in the United States, is the age-related loss of near vision that typically becomes noticeable in people over 45. For investors seeking deeper insights, InvestingPro offers comprehensive analysis with 14+ additional ProTips and a detailed Pro Research Report covering LENZ’s market position and growth potential.
According to the company, VIZZ works by contracting the iris sphincter muscle to create a pinhole effect that extends depth of focus. In clinical trials, 93% of participants achieved 20/40 or better near vision within 30 minutes, with effects lasting up to 10 hours.
"We are thrilled to introduce VIZZ to the 128 million adults living with blurry near vision in the United States," said Eef Schimmelpennink, President and CEO of LENZ Therapeutics, in the press release.
The most common reported adverse reactions in clinical trials included instillation site irritation (20%), dim vision (16%), and headache (13%).
LENZ Therapeutics is focused on commercializing VIZZ in the United States while establishing licensing partnerships internationally. The company reports that presbyopia affects an estimated 1.8 billion people globally.
This article is based on a press release issued by LENZ Therapeutics. Based on InvestingPro’s Fair Value analysis, LENZ appears to be trading above its calculated Fair Value, with the stock showing particularly strong momentum in recent months, gaining over 74% in the past six months.
In other recent news, LENZ Therapeutics has made significant strides with the FDA approval of VIZZ, its aceclidine-based eye drop for presbyopia. This approval marks VIZZ as the first and only aceclidine-based treatment for blurry near vision, with plans to introduce samples in the U.S. by October 2025 and full commercial availability by the end of the year. Following this development, H.C. Wainwright raised its price target for LENZ Therapeutics from $48 to $56, maintaining a Buy rating and highlighting the company as a top pick for the second half of 2025. Additionally, LENZ reported a second-quarter loss of $0.53 per share as it gears up for the potential launch of its product. The company has already completed the hiring and training of an 88-member sales force in anticipation of commercialization. LENZ Therapeutics also confirmed that its New Drug Application for LNZ100 is on track for an FDA decision by August 2025. The company ended the quarter with a robust cash reserve of $209.6 million, expected to support operations until achieving positive cash flow post-launch.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.